Literature DB >> 31043274

Paris Interobserver Reproducibility Study (PIRST).

Daniel F I Kurtycz1, Güliz A Barkan2, Derek M Pavelec3, Dorothy L Rosenthal4, Eva M Wojcik2, Christopher J VandenBussche4, Kala Mangiulli5, Matthew T Olson6.   

Abstract

OBJECTIVES: In concert with the 2015 publication of The Paris System for Urinary Cytopathology (TPS), a Web-based interobserver study, co-sponsored by the American Society of Cytopathology (ASC) and International Academy of Cytology (IAC), was performed to determine diagnostic agreement among volunteer participants and with the TPS author consensus.
MATERIAL AND METHODS: Participants at various levels of training and certification were recruited through national and international cytopathology professional societies. Although the survey was open to all comers, potential participants were screened by two basic cytopathology questions. Information was collected on the level of training, practice patterns, and experience. Study participants evaluated 85 images (previously unpublished) chosen from the TPS atlas. These images spanned all diagnostic categories.
RESULTS: Of the 1993 attempts to access the survey, 1313 participants correctly answered the qualifying questions and were included in the survey. Respondents were concentrated in the United States, although many participants came from other countries. The majority of respondents were board-certified in anatomic pathology with cytopathology certification. A smaller number were cytotechnologists. Board-certified cytopathologists and specialist cytotechnologists outperformed other certifications. Practice type (academics versus non-academic), and country (US versus international) were not major factors in concordance. Diagnostic categories with the best agreement were Negative for High-Grade Urothelial Carcinoma (NHGUC; 71%), Low-Grade Urothelial Neoplasm (LGUN; 62%), and High-Grade Urothelial Carcinoma (HGUC; 57%). Indeterminate categories showed low concordance.
CONCLUSIONS: The NHGUC, LGUN, and HGUC were most correlated with diagnostic agreement among observers. This study can serve as a baseline for future comparisons.
Copyright © 2018 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Interobserver reproducibility; Standardized Terminology System; The Paris System; Urine cytology; Web Based Image Study

Year:  2018        PMID: 31043274     DOI: 10.1016/j.jasc.2018.02.005

Source DB:  PubMed          Journal:  J Am Soc Cytopathol        ISSN: 2213-2953


  5 in total

1.  Milan Interobserver Reproducibility Study (MIRST): Milan System 2018.

Authors:  Daniel F I Kurtycz; Ester Diana Rossi; Zubair Baloch; Derek Pavelec; Emilio Madrigal; Philippe Vielh; William Faquin
Journal:  J Am Soc Cytopathol       Date:  2020-02-11

Review 2.  The Diagnostic Dilemma of Urothelial Tissue Fragments in Urinary Tract Cytology Specimens.

Authors:  Derek B Allison; M Lisa Zhang; Poonam Vohra; Christopher J VandenBussche
Journal:  Diagnostics (Basel)       Date:  2022-04-08

3.  Impact of the Paris system for reporting urine cytopathology on predictive values of the equivocal diagnostic categories and interobserver agreement.

Authors:  Rania Bakkar; James Mirocha; Xuemo Fan; David P Frishberg; Mariza de Peralta-Venturina; Jing Zhai; Shikha Bose
Journal:  Cytojournal       Date:  2019-10-22       Impact factor: 2.091

4.  Comparison of Diagnostic Performances of Urine Cytology Before and After the Use of The Paris System Criteria: An Institutional Experience from Turkey.

Authors:  Sevgen Onder; Olcay Kurtulan; Altan Kavuncuoglu; Bulent Akdogan
Journal:  J Cytol       Date:  2021-08-23       Impact factor: 1.000

5.  Diagnostic Agreement for High-Grade Urothelial Cell Carcinoma in Atypical Urine Cytology: A Nationwide Survey Reveals a Tendency for Overestimation in Specimens with an N/C Ratio Approaching 0.5.

Authors:  Yeh-Han Wang; Jen-Fan Hang; Chien-Hui Wen; Kuan-Cho Liao; Wen-Ying Lee; Chiung-Ru Lai
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.